RxDoctor Payments Data

Svetlana Stahl

Acute Care · Toledo, OHNPI 1376821058

Payments from drug & device makers

$392in general payments, 2019–2025

Across 17 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$178
  • Boston Scientific$89
  • AbbVie$41
  • Lundbeck LLC$21
  • AstraZeneca$17
  • Mannkind Corporation$16
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$392100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$392 in reported general payments places this provider in the 60th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$100,783
Medicare patients
210
Services billed
1,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$112,090
TrulicityDulaglutide29$28,637
LokelmaSodium Zirconium Cyclosilicate34$23,073
MyrbetriqMirabegron49$20,542
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog68$17,504
FarxigaDapagliflozin Propanediol57$16,613
Lacosamide54$15,348
JanuviaSitagliptin Phosphate45$14,504
Breo ElliptaFluticasone/Vilanterol31$12,887
NuedextaDextromethorphan Hbr/Quinidine18$12,182
XareltoRivaroxaban28$11,206
Combivent RespimatIpratropium/Albuterol Sulfate20$11,204
VelphoroSucroferric Oxyhydroxide13$10,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,317
Memantine Hcl143$10,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$17$39,68591 claims
AbbVieRestasis, Creon$41$12,57544 claims
Avanir Pharmaceuticals, Inc.Nuedexta$15$12,18218 claims
Mannkind CorporationAfrezza$16$6,63812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,101 acute care providers in Ohio.

Other acute care in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →